Pull to refresh
Logo
What Changed
Following Why Sign Up
AstraZeneca COPD drug cuts flare-ups across all patient types in late-stage trials

AstraZeneca COPD drug cuts flare-ups across all patient types in late-stage trials

New Capabilities

Tozorakimab reduced moderate-to-severe exacerbations by up to 34% and worked regardless of eosinophil levels, unlike existing biologics

September 9th, 2026: Results published in NEJM; FDA review underway

Overview

Updated Sep 10

Millions of COPD patients who don't respond to current biologic treatments may soon have a new option. AstraZeneca's tozorakimab cut moderate-to-severe flare-ups by 29% to 34% in two late-stage trials, and unlike existing biologics, it worked across all blood eosinophil levels.

The drug blocks IL-33, a protein that drives airway inflammation and mucus production. If approved, it would be the first COPD biologic available to patients with low eosinophil counts, expanding treatment to millions who currently have no biologic option.

Why it matters

If approved, tozorakimab would be the first COPD biologic that works regardless of eosinophil levels, giving millions of patients a new option.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

29-34%
Reduction in moderate-to-severe COPD flare-ups (former smokers)
Primary endpoint in OBERON and TITANIA trials, compared with placebo on top of inhaled standard of care.
2,306
Patients randomized across both Phase III trials
Included current and former smokers across all eosinophil counts and lung function severities.
Q1 2027
Expected FDA decision (PDUFA date)
Biologics License Application accepted for Priority Review with a Priority Review voucher.
16-26M
Americans living with COPD
Diagnosed and undiagnosed cases, per AstraZeneca. COPD is the fifth-leading cause of death in the US.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Frank Sciurba
Frank Sciurba
Professor of Pulmonary and Critical Care Medicine, University of Pittsburgh; Chief Investigator of the LUNA program
Led the OBERON and TITANIA Phase III trials
RD
Ruud Dobber
Senior executive, AstraZeneca BioPharmaceuticals
Announced regulatory review progress for tozorakimab

Organizations Involved

AstraZeneca
AstraZeneca
Pharmaceutical company
Developer of tozorakimab

British-Swedish pharmaceutical company developing tozorakimab, a monoclonal antibody targeting IL-33.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulator
Reviewing tozorakimab BLA under Priority Review

US regulator reviewing tozorakimab for COPD approval, with a PDUFA date expected in Q1 2027.
University of Pittsburgh School of Medicine
University of Pittsburgh School of Medicine
Medical school
Co-led the OBERON and TITANIA trials

Academic institution whose researchers co-led the Phase III trials of tozorakimab.

Timeline

December 2024 September 2026

3 events Latest: September 9th, 2026 · 2 months ago

  1. Results published in NEJM; FDA review underway

    Latest Publication

    Full results published in the New England Journal of Medicine. BLA under Priority Review with PDUFA date expected Q1 2027.

  2. Tozorakimab Phase III results presented at ERS 2026

    Clinical Trial

    AstraZeneca presented OBERON and TITANIA results in Barcelona, showing 29-34% reduction in moderate-to-severe COPD flare-ups in former smokers.

  3. FDA grants Fast Track designation for tozorakimab in COPD

    Regulatory

    The FDA granted Fast Track designation for tozorakimab as a COPD treatment, speeding up development and review.

Scenarios

1

FDA approves tozorakimab for COPD in Q1 2027

Likely Resolves by Q1 2027

Discussed by: AstraZeneca executives and industry analysts

The BLA is under Priority Review with a PDUFA date in Q1 2027. Strong efficacy across all eosinophil levels and a safety profile similar to placebo make approval the most likely outcome. Approval would make tozorakimab the first COPD biologic available to patients with low eosinophil counts.

2

FDA delays tozorakimab decision, requests more data

Possible Resolves by Q2 2027

Discussed by: Regulatory analysts and investors

Despite strong results, the FDA could extend the review or issue a Complete Response Letter. Questions about how to position the drug relative to Dupixent in high-eosinophil patients could factor into the review.

3

AstraZeneca launches head-to-head trial against Dupixent in COPD

Possible Resolves by End of 2027

Discussed by: Analysts quoted by CNBC

With no head-to-head data, doctors will need to decide whether to use tozorakimab before or after Dupixent in high-eosinophil patients. A comparative trial would settle the question and could expand tozorakimab's market share.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

September 2024

Dupixent COPD approval (2024)

Sanofi and Regeneron's dupilumab (Dupixent) became the first biologic approved for COPD, but only for patients with high blood eosinophil counts. The approval followed trials showing reduced exacerbations in that subset.

Then

Dupixent became the standard biologic for eosinophilic COPD.

Now

It established biologics as a COPD treatment but left most patients without a biologic option.

Why this matters now

Tozorakimab aims to expand biologic treatment to all COPD patients, including the majority who don't qualify for Dupixent.

2019-2026

IL-33 inhibitor struggles (2019-2026)

Multiple companies pursued IL-33 inhibitors for respiratory disease with limited success, leading investors and researchers to question whether the target was viable. Roche's astegolimab remains in Phase III.

Then

Several programs stalled or failed to meet endpoints.

Now

IL-33 became seen as a risky target for respiratory biologics.

Why this matters now

Tozorakimab's Phase III success suggests its dual-pathway mechanism may overcome the limitations of earlier IL-33 drugs.

Sources

(11)
+5
Reuters CNBC Bloomberg Medical Daily Clinical Trials Arena Medical Xpress BioSpace RTT News SRN News Nova Pharma News Human Progress